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Thyroid cancer is the most common endocrine malignancy
and accounts for approximately 44,670 cases and 1,690
deaths in 2010 per the ACS. The purpose of this special issue
is to provide an update on recent advances in the under-
standing of thyroid tumorigenesis and their implications
in clinical practice and new surgical approaches to thyroid
cancer and to the adoption of techniques used successfully
in other tumor types for use in patients with thyroid cancer.
Invited papers addressed several of the above topics.
Advances in surgery promise to allow expanded surgical
treatment options and potentially make thyroid cancer
surgery safer and better accepted by patients. Lang et al. pro-
vide a detailed overview of reﬁnement in surgical techniques
including endoscopic thyroidectomy techniques, the addi-
tion of the da Vinci robot, and the use of operative adjuncts
in thyroid surgery such as intraoperative neuromonitoring
and quick intraoperative parathyroid hormone. They also
outline the clinical studies needed to better analyze the
use of this new technology and its relative beneﬁts and
risks. Lombardi et al. present their review of a large series
of patients with papillary thyroid cancer who underwent
video-assisted thyroidectomy (VAT) for completeness of the
surgical resection and short-to-medium term recurrence.
Their results, while retrospective, seem to indicate that
VAT is feasible and safe and may be a valid alternative to
conventional surgery for small PTC. No surgical approach
is without its concomitant risks—in thyroid surgery, this
includes injury to one or both recurrent laryngeal nerves
which can result in poor voice quality and the potential for
recurrent aspiration. Sanuki et al. discuss their ﬁndings of
immediate reconstruction of the recurrent laryngeal nerve
during thyroid cancer surgery in terms of voice outcomes
using videostroboscopic, aerodynamic, and perceptual anal-
yses. While their numbers were small, it addresses an im-
portant questionoften raised in surgery asto whether imme-
diate or delayed reconstruction should be performed.
Advances in genomics have oﬀered exciting insights into
thebiologyofthyroid cancer.While much attentionhasbeen
focused on thetraditional nucleic acids, the study ofproteins
and their function has been relatively neglected, in part due
to the diﬃculty of the techniques required. The paper by
Miyoshi et al. provides a comprehensive overview of the
vitalroleofglycosylationandfunctional glycomicsinthyroid
cancer.
As clinicianswell know, an accurate cytological diagnosis
is key to the treatment approach for patients with thyroid
nodules; this diagnosis is based on distinctive cytologi-
cal features in combination with immunocytochemistry.
Pazaitou-Panayiotou and colleagues present here their study
of 83 thyroid cancer ﬁne needle aspirations using Thin
Layer Cytology. They present data on a panel of immuno-
markers (including Cytokeratin-19, Galectin-3, HBME1,
CD-44,CD-56,andE-Cadherin)anddescribethispromising
new technique to improve diagnostic accuracy.
Early detection is a key component of familial thyroid
cancer; Bonora et al. provide us with an excellent review of2 Journal of Oncology
the familial syndromes, genetic abnormalities, and risk fac-
tors proposed to increase the likelihood of this type of
neoplasia. Giovanella et al. present a very interesting case
exampleofararefunctioningtrabeculartumorofthethyroid
gland which serves as a reminder to us that we must not
overlook the potential for malignancy in the high-uptake
pertechnetate positive nodule.
While the most extensively studied pathway for targeted
therapy in thyroid cancer is RAS/RAF/MEK, clinical trials
targeting therapies in this pathway are relatively new. The
review by Poon and Tai provides us with a comprehensive
updateofknowngenomicchangesinthyroidcancerandhow
this information is being used in clinical trials to improve
targeted therapy.
Treatment of certain subtypes of thyroid cancer has
been limited in part due to a dearth in therapeutic strate-
gies. In a seminal paper, Dr. Steven Rosenberg proposed
the concept that the body’s immune system could be
manipulated for cancer therapy. (Rosenberg SA (Jan 1984).
“Adoptive immunotherapy of cancer: accomplishments and
prospects”. Cancer Treat Rep 68 (12): 233–55). Since then,
a wide variety of immunotherapeutic approaches have been
tested in clinical trials, in particular using either cell-based
therapy or immunomodulators. These have led to fairly
modest improvements in patient outcomes and a number
of therapeutic challenges. This initial work has set the basis
for a vigorous research eﬀort to better understand the
complex relationship and numerous intersecting pathways
which regulate the body’s response not only to cancer but
to therapy for cancer as well. In their excellent review
of dendritic cell-based immunotherapy for the subset of
advanced, metastatic, or undiﬀerentiated and anaplastic
thyroidcarcinoma,Papewalisetal.provideuswithafocuson
understanding the advances of antitumor immune response
in thyroid carcinoma and well summarizes the rationale
for adoptive dendritic cell transfer including the technical
approach to this interesting new modality of treatment.
We hope that this special issue will educate, stimulate,
and inspire support for participation in clinical trials and
new research in the ﬁeld of thyroid cancer. The development
of new surgical approaches, eﬀective targeted therapies,
and better preventive interventions will assist in improving
treatment and outcome in patients with thyroid cancer.
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